GYG1 and Sepsis: Kaplan–Meier survival analysis revealed that Gyg1 silencing markedly improved survival compared to both untreated and LNP-control siRNA-treated groups (Figure 9H), suggesting that metabolic targeting of Gyg1 may offer therapeutic benefit in sepsis.